MA37894B1 - Protéines de fusion d'interleukine-2 et leurs utilisations - Google Patents

Protéines de fusion d'interleukine-2 et leurs utilisations

Info

Publication number
MA37894B1
MA37894B1 MA37894A MA37894A MA37894B1 MA 37894 B1 MA37894 B1 MA 37894B1 MA 37894 A MA37894 A MA 37894A MA 37894 A MA37894 A MA 37894A MA 37894 B1 MA37894 B1 MA 37894B1
Authority
MA
Morocco
Prior art keywords
fusion proteins
interleukin
methods
present
relates
Prior art date
Application number
MA37894A
Other languages
English (en)
Other versions
MA37894A1 (fr
Inventor
Ralf Hosse
Ekkehard Moessner
Pablo Umana
Christian Klein
Laurence Bernard Peterson
Linda Wicker
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48948417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37894(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MA37894A1 publication Critical patent/MA37894A1/fr
Publication of MA37894B1 publication Critical patent/MA37894B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne en général des protéines de fusion d'immunoglobulines et d'interleukine-2 (il-2). De plus, la présente invention concerne des polynucléotides codant pour de telles protéines de fusion, et des vecteurs et cellules hôtes comprenant de tels polynucléotides. L'invention concerne en outre des procédés de production des protéines de fusion de l'invention, et leurs procédés d'utilisation dans le traitement d'une maladie.
MA37894A 2012-08-10 2013-08-07 Protéines de fusion d'interleukine-2 et leurs utilisations MA37894B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681676P 2012-08-10 2012-08-10
PCT/EP2013/066516 WO2014023752A1 (fr) 2012-08-10 2013-08-07 Protéines de fusion d'interleukine-2 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA37894A1 MA37894A1 (fr) 2018-07-31
MA37894B1 true MA37894B1 (fr) 2020-01-31

Family

ID=48948417

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37894A MA37894B1 (fr) 2012-08-10 2013-08-07 Protéines de fusion d'interleukine-2 et leurs utilisations

Country Status (22)

Country Link
US (4) US20140044675A1 (fr)
EP (1) EP2882458B1 (fr)
JP (1) JP6526561B2 (fr)
KR (1) KR20150041628A (fr)
CN (2) CN104507504A (fr)
AR (1) AR092089A1 (fr)
AU (1) AU2013301562B2 (fr)
BR (1) BR112015002765A2 (fr)
CA (1) CA2873291A1 (fr)
CL (1) CL2014003322A1 (fr)
CO (1) CO7121348A2 (fr)
CR (1) CR20140532A (fr)
EA (1) EA201500206A1 (fr)
HK (1) HK1208827A1 (fr)
IL (1) IL236933A0 (fr)
MA (1) MA37894B1 (fr)
MX (1) MX2015001749A (fr)
PE (1) PE20150752A1 (fr)
PH (1) PH12014502767A1 (fr)
SG (1) SG11201407579QA (fr)
TW (1) TW201420607A (fr)
WO (1) WO2014023752A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CA2894511C (fr) 2012-12-11 2021-12-07 Albert Einstein College Of Medicine Of Yeshiva University Procedes pour identification de recepteur/ligand a rendement eleve
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
AU2015301936B2 (en) * 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
PT3328894T (pt) * 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
RU2018124307A (ru) 2015-12-04 2020-01-14 Новартис Аг Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
WO2017201210A1 (fr) 2016-05-18 2017-11-23 Cue Biopharma, Inc. Polypeptides multimères modulateurs des lymphocytes t et leurs procédé d'utilisation
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
EP3538548A4 (fr) 2016-11-08 2020-08-19 Delinia, Inc. Variants d'il-2 pour le traitement de maladies auto-immunes
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (fr) 2017-01-09 2021-01-27 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2019147837A2 (fr) 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Protéines de fusion de cytokines
EP3752178A1 (fr) 2018-02-16 2020-12-23 Iltoo Pharma Utilisation de l'interleukine 2 pour traiter le syndrome de sjögren
EP3765517A1 (fr) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles se liant à calréticuline et utilisations associees
PE20210313A1 (es) 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
WO2020007937A1 (fr) 2018-07-03 2020-01-09 Iltoo Pharma Utilisation de l'interleukine-2 pour le traitement de la sclérose systémique
CA3105448A1 (fr) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Molecules d'anticorps anti-tcr et leurs utilisations
US12403181B2 (en) 2018-08-13 2025-09-02 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
WO2020127277A1 (fr) 2018-12-18 2020-06-25 Robert Koch-Institut Cellule présentatrice du cmh-i chargée de peptides et il-2 présentant une demi-vie prolongée pour amplifier une réponse immunitaire cytotoxique cellulaire
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
IL308185B2 (en) 2020-02-16 2026-03-01 Aulos Bioscience Inc Engineered antibodies against IL-2
JP7840267B2 (ja) 2020-03-06 2026-04-03 サントル、オスピタリエ、ユニヴェルシテール、ド、ニーム 筋萎縮性側索硬化症の治療のための低用量ヒトインターロイキン－２
WO2021231376A2 (fr) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs méthodes d'utilisation
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
CN113912734B (zh) * 2020-07-08 2025-02-28 南京师范大学 融合多肽及其用途
WO2022056014A1 (fr) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Polypeptides multimères modulateurs des lymphocytes t du cmh de classe ii pour le traitement du diabète sucré de type 1 (dt1) et leurs procédés d'utilisation
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
CN112724259B (zh) * 2020-11-16 2022-12-20 天津林达生物科技有限公司 人血清白蛋白与白介素2的融合蛋白及其用途
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents
US20240148827A1 (en) * 2021-03-11 2024-05-09 The Methodist Hospital Methods and Compositions for Treatment of Disease
CN113248610B (zh) * 2021-05-14 2022-08-16 厦门柏慈生物科技有限公司 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途
CN115947820A (zh) * 2021-10-08 2023-04-11 北京志道生物科技有限公司 一种水溶性提高的il-2衍生物
WO2024008126A1 (fr) * 2022-07-06 2024-01-11 Elpiscience (Suzhou) Biopharma, Ltd. Mutéines d'il2 et leurs utilisations
CN117003852B (zh) * 2022-07-07 2024-11-05 北京大学 白细胞介素-2的拓扑改造及其作为自身免疫病药物的应用
EP4587043A1 (fr) 2022-09-12 2025-07-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Interleukine-2 pour le traitement des troubles du spectre autistique
KR20240055222A (ko) * 2022-10-19 2024-04-29 주식회사 에이프릴바이오 인터루킨-2 변이 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
CN117986383A (zh) * 2022-11-02 2024-05-07 北京昌平实验室 融合蛋白及其应用
IL320648A (en) * 2022-11-10 2025-07-01 Aulos Bioscience Inc Methods of using antibodies against IL-2
EP4630035A1 (fr) 2022-12-05 2025-10-15 Centre Hospitalier Universitaire de Nimes Interleukine-2 humaine à faible dose pour traitement de la sclérose latérale amyotrophique dans un sous-groupe de patients
JP2026503077A (ja) 2023-01-09 2026-01-27 オデッセイ セラピューティクス，インコーポレイテッド 抗ｔｎｆｒ２抗原結合タンパク質及びその使用
WO2025217240A1 (fr) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène anti-tnfr2 et leurs utilisations
WO2026006809A1 (fr) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Molécules multispécifiques se liant à tnfr2 et cd25 et leurs utilisations
CN120424884B (zh) * 2025-07-10 2025-11-04 上海惠盾因泰生物科技有限公司 表达分泌型il-2融合蛋白的工程化til及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2388385B1 (fr) 1977-04-18 1982-01-08 Hitachi Metals Ltd Piece d'ornement fixee par des aimants permanents
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS60502136A (ja) * 1983-08-10 1985-12-12 アムジエン　インコーポレイテツド 微生物によるインタ−ル−キン２の形質発現
WO1985000817A1 (fr) 1983-08-10 1985-02-28 Amgen Expression microbienne de l'interleukine ii
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
HUP0100813A3 (en) * 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US20060234205A1 (en) 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
EP1740615B1 (fr) 2004-03-31 2014-11-05 Genentech, Inc. Anticorps anti-tgf-beta humanises
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JP2008521814A (ja) * 2004-11-24 2008-06-26 シェーリング コーポレイション Ｄａｐ−１０およびその使用
AU2007271398B2 (en) * 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
JP2010534469A (ja) 2007-07-25 2010-11-11 アストラゼネカ アクチボラグ Ｋｄｒ指向性標的化結合物質およびその使用
WO2009061853A2 (fr) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Polypeptides d'interleukine-2 (il-2) mutants
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
AU2010206840B2 (en) 2009-01-21 2015-02-05 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CA2806021C (fr) 2010-08-13 2019-05-21 Roche Glycart Ag Anticorps anti-fap et procedes d'utilisation
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
DK2683395T3 (en) 2011-03-11 2018-11-19 Hopitaux Paris Assist Publique USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2723380B1 (fr) 2011-06-24 2019-08-21 Stephen D. Gillies Protéines hybrides d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
CN104507504A (zh) 2015-04-08
CN111635460A (zh) 2020-09-08
PH12014502767A1 (en) 2015-02-09
JP6526561B2 (ja) 2019-06-05
IL236933A0 (en) 2015-03-31
EA201500206A1 (ru) 2016-04-29
EP2882458A1 (fr) 2015-06-17
US20160090407A1 (en) 2016-03-31
US10562949B2 (en) 2020-02-18
AU2013301562A1 (en) 2014-11-20
JP2015530984A (ja) 2015-10-29
CL2014003322A1 (es) 2015-02-13
KR20150041628A (ko) 2015-04-16
SG11201407579QA (en) 2014-12-30
US20200172591A1 (en) 2020-06-04
US20180009868A1 (en) 2018-01-11
CR20140532A (es) 2015-01-12
US11365232B2 (en) 2022-06-21
PE20150752A1 (es) 2015-05-15
HK1208827A1 (en) 2016-03-18
CO7121348A2 (es) 2014-11-20
TW201420607A (zh) 2014-06-01
BR112015002765A2 (pt) 2018-03-13
EP2882458B1 (fr) 2018-07-11
MX2015001749A (es) 2015-06-05
AR092089A1 (es) 2015-03-25
WO2014023752A1 (fr) 2014-02-13
US20140044675A1 (en) 2014-02-13
AU2013301562B2 (en) 2017-04-06
CA2873291A1 (fr) 2014-02-13
MA37894A1 (fr) 2018-07-31

Similar Documents

Publication Publication Date Title
MA37894B1 (fr) Protéines de fusion d'interleukine-2 et leurs utilisations
MA20150232A1 (fr) Protéines de fusion de l'interleukine-10 et leurs utilisations
PH12017501583B1 (en) Novel proteins specific for cd137
MA38406B1 (fr) Virus de la maladie de newcastle et leurs utilisations
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MX378747B (es) Complejos de proteínas de citomegalovirus.
MA38308B1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
MA35130B1 (fr) Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri)
MX384075B (es) Nuevas proteínas específicas para la angiogénesis.
PH12014502184A1 (en) Anti-hla-b* 27 antibodies and uses thereof
BR112014026755B8 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
EA201590247A1 (ru) Антитела к siglec-15
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
MA40283A (fr) Aptamères spécifiques du récepteur tlr-4 et leurs utilisations
MX2015005384A (es) Miembros de union para il-1 beta.
MA34827B1 (fr) Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes
MA35935B1 (fr) Oligonucléotides pour moduler l'expression de gènes et leurs utilisations
MA46819B1 (fr) Streptococcus thermophilus pour utilisation dans la préparation de produits fermentés
CY1116962T1 (el) Ανθρωπινες λευκολεκτινες και χρησεις αυτων
FR2986229B1 (fr) Nouveaux monergols ioniques a base de n2o pour la propulsion spatiale
FR3046417B1 (fr) Polyester epaississant et/ou rheofluidifiant
FR3046728B1 (fr) Nouvelles nanoparticules d'organosilice mesoporeuses, leur methode de preparation et leurs utilisations.
EA201001567A1 (ru) Инкапсуляция биологически активных агентов
MA34380B1 (fr) Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine